powered by
▸
healthparse
Search
Cohort Builder
Tools
▾
KOL Finder
Territories
Drug Compare
AI Query
Research
Browse
▾
By state
By specialty
Pricing
Search
Cohort Builder
Tools
KOL Finder
Territories
Drug Compare
AI Query
Research
Browse
By state
By specialty
Pricing
PROVIDER PROFILE · NPI 1124462486
Rahel Demisse
M.D.
Medical Oncology
Los Angeles,
CA
I
CROSS-REFERENCE
Related data on other Healthparse brands
ProviderScore
OIG/SAM exclusion screening, sanctions history
Healthparse Signals
Monitor this provider for changes — dated NPI change events
QUALITY · MIPS · 2024
Final MIPS score
88.9
Quality
72.1
Cost
77.4
Improvement activities
40.0
Promoting interop.
80.0
Payment adjustment
0.58%
Group
FACILITY AFFILIATIONS
Hospital & Facility Affiliations (1)
CCN 050292
Hospital
PRESCRIBING · PART D · 2024
Total Rx claims
101
Beneficiaries
—
Total drug cost
$400K
Distinct drugs
5
Brand share
43.6%
Top prescribed drugs
Enzalutamide
29 claims
Anastrozole
23 claims
Ondansetron Hcl
21 claims
Loperamide Hcl
15 claims
Prochlorperazine Maleate
13 claims
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$245
Payment records
10
By payment type
Food and Beverage
$245
Top paying entities
Food and Beverage
$245
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
95
Unique beneficiaries
—
Total services
219
Distinct HCPCS
4
Medicare payment
$8K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 268 Medical Oncology providers in CA — bottom quintile (cohort median 1,130).
